Previous Section
Drug Therapy
11. Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes.
- Author
- Kurtin S; Sokol L;
- Institution
- University of Arizona, Arizona Cancer Center, Tucson, 85724, USA. skurtin@umcaz.edu
- Journal
- Cancer Control. 2006 Dec;13 Suppl:26-31.
- Abstract URL
- Click here to view abstract
12. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
- Author
- Fenaux P; Raza A; Mufti GJ; Aul C; Germing U; Kantarjian H; Cripe L; Kerstens R; De Porre P; Kurzrock R;
- Institution
- Journal
- Blood. 2007 May 15;109(10):4158-63. Epub 2007 Jan 30.
- Abstract URL
- Click here to view abstract
13. Thalidomide therapy in adult patients with myelodysplastic syndrome: a north central cancer treatment group phase II trial.
- Author
- Musto P;
- Institution
- Journal
- Cancer. 2007 Mar 15;109(6):1211-2; author reply 1212.
14. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
- Author
- Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA; Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
- Institution
- Division of Hematology/Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA. lewis.silverman@mssm.edu
- Journal
- J Clin Oncol. 2006 Aug 20;24(24):3895-903.
- Abstract URL
- Click here to view abstract
Next: Clinical Trials
